Literature DB >> 15913847

Synthesis and anticancer evaluation of certain 4-anilinofuro[2,3-b]quinoline and 4-anilinofuro[3,2-c]quinoline derivatives.

Yeh-Long Chen1, I-Li Chen, Tai-Chi Wang, Chein-Hwa Han, Cherng-Chyi Tzeng.   

Abstract

Certain linear 4-anilinofuro[2,3-b]quinoline and angular 4-anilinofuro[3,2-c]quinoline derivatives were synthesized and evaluated in vitro against the full panel of NCI's 60 cancer cell lines. For the linear 4-anilinofuro[2,3-b]quinoline derivatives, 1-[4-(furo[2,3-b]quinolin-4-ylamino)phenyl]ethanone (5a) is the most cytotoxic with a mean GI50 value of 0.025 microM. Substitution at either furo[2,3-b]quinoline ring (2a, 2b, and 5b) or 4-anilino moiety (3-7) led to a decrease of cytotoxicity. For the angular 4-anilinofuro[3,2-c]quinoline derivatives, (E)-1-[3-(furo[3,2-c]quinolin-4-ylamino)phenyl]ethanone oxime (14a) exhibited potent inhibitory activities on UO-31, UACC-257, and UACC-62, with GI50 values of 0.03,<0.01, and<0.01 microM respectively. The same cytotoxicity profile was observed for its methyl counterpart, 14b, in which the GI50 values against UO-31, UACC-257, and UACC-62 was<0.01, 0.04 and<0.01 microM respectively. These results deserve full attention especially because 14a and 14b are relatively non-cytotoxic with the mean GI50 value of 7.73 and 8.91 microM respectively.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15913847     DOI: 10.1016/j.ejmech.2005.04.003

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  5 in total

1.  Novel CIL-102 derivatives as potential therapeutic agents for docetaxel-resistant prostate cancer.

Authors:  Dannah R Miller; Cherng-Chyi Tzeng; Trey Farmer; Evan T Keller; Steve Caplan; Yu-Shuin Chen; Yeh-Long Chen; Ming-Fong Lin
Journal:  Cancer Lett       Date:  2018-08-03       Impact factor: 8.679

2.  Modification of polyethylene glycol onto solid lipid nanoparticles encapsulating a novel chemotherapeutic agent (PK-L4) to enhance solubility for injection delivery.

Authors:  Yi-Ping Fang; Pao-Chu Wu; Yaw-Bin Huang; Cherng-Chyi Tzeng; Yeh-Long Chen; Yu-Han Hung; Ming-Jun Tsai; Yi-Hung Tsai
Journal:  Int J Nanomedicine       Date:  2012-09-17

3.  Amsacrine analog-loaded solid lipid nanoparticle to resolve insolubility for injection delivery: characterization and pharmacokinetics.

Authors:  Yi-Ping Fang; Chih-Hung Chuang; Pao-Chu Wu; Yaw-Bin Huang; Cherng-Chyi Tzeng; Yeh-Long Chen; Ya-Ting Liu; Yi-Hung Tsai; Ming-Jun Tsai
Journal:  Drug Des Devel Ther       Date:  2016-03-04       Impact factor: 4.162

4.  CIL-102-Induced Cell Cycle Arrest and Apoptosis in Colorectal Cancer Cells via Upregulation of p21 and GADD45.

Authors:  Wen-Shih Huang; Yi-Hung Kuo; Hsing-Chun Kuo; Meng-Chiao Hsieh; Cheng-Yi Huang; Ko-Chao Lee; Kam-Fai Lee; Chien-Heng Shen; Shui-Yi Tung; Chih-Chuan Teng
Journal:  PLoS One       Date:  2017-01-09       Impact factor: 3.240

5.  Identification of Two Novel CIL-102 Upregulations of ERP29 and FUMH to Inhibit the Migration and Invasiveness of Colorectal Cancer Cells by Using the Proteomic Approach.

Authors:  Kung-Chuan Cheng; Hsing-Chun Kuo; Meng-Chiao Hsieh; Cheng-Yi Huang; Chih-Chuan Teng; Shui-Yi Tung; Chien-Heng Shen; Kam-Fai Lee; Ya-Ling Yang; Ko-Chao Lee
Journal:  Biomolecules       Date:  2021-08-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.